The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II study of durvalumab and stereotactic ablative body radiotherapy (SABR) in locally advanced pancreatic adenocarcinoma (LA PDAC).
 
Fergus Keane
No Relationships to Disclose
 
Joshua David Schoenfeld
No Relationships to Disclose
 
Fionnuala Crowley
No Relationships to Disclose
 
Catherine Anne O'Connor
No Relationships to Disclose
 
Charlie White
No Relationships to Disclose
 
Carly Schwartz
No Relationships to Disclose
 
Robin Brenner
No Relationships to Disclose
 
Mary Larsen
No Relationships to Disclose
 
Wungki Park
Consulting or Advisory Role - Aegle; onconic therapeutics
Research Funding - Astellas Pharma (Inst); Gossamer Bio (Inst); Merck (Inst)
 
Anna M. Varghese
Consulting or Advisory Role - Lilly (I); Roche (I)
Research Funding - BioMed Valley Discoveries; Bristol-Myers Squibb; Illumina (I); Lilly; Silenseed; Verastem
Travel, Accommodations, Expenses - Roche (I)
 
Kenneth H. Yu
Consulting or Advisory Role - Ipsen
Research Funding - General Oncology (Inst); Ipsen; OncoC4 (Inst); Senhwa Biosciences (Inst)
 
Jia Li
No Relationships to Disclose
 
Alice Zervoudakis
No Relationships to Disclose
 
Zoe Goldberg
No Relationships to Disclose
 
Joanne F. Chou
No Relationships to Disclose
 
Santosha Vardhana
Honoraria - Agios
Consulting or Advisory Role - ADC Therapeutics; Immunai
 
Marsha Reyngold
Research Funding - Elekta
 
Christopher H Crane
No Relationships to Disclose
 
Richard Tuli
No Relationships to Disclose
 
Eileen Mary O'Reilly
Consulting or Advisory Role - Adicet Bio (I); Alnylam (I); AstraZeneca; Autem Medical (I); BeiGene (I); Berry Genomics (I); BioSapien; BioSapien; Boehringer Ingelheim; Cend Therapeutics; CytomX Therapeutics; CytomX Therapeutics; Eisai (I); Exelixis (I); Flatiron Health (I); Genentech/Roche (I); Genoscience Pharma (I); Helio Health (I); IDEAYA Biosciences; Incyte (I); Ipsen; Legend Biotech (I); Merck; Nerviano Medical Sciences (I); Novartis; Noxxon Pharma; QED Therapeutics (I); Rafael Pharmaceuticals; RedHill Biopharma (I); Seagen; Thetis Pharma; Yiviva (I)
Research Funding - Arcus Ventures (Inst); AstraZeneca/MedImmune (Inst); BioNTech (Inst); Celgene (Inst); Elicio Therapeutics (Inst); Genentech (Inst); Parker Institute for Cancer Immunotherapy (Inst); Roche (Inst); Silenseed (Inst)
(OPTIONAL) Uncompensated Relationships - Thetis Pharma